AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 151 min read$ATNM

Actinium Pharmaceuticals Names Matt David CFO

Actinium Pharmaceuticals (ATNM) named Matt David as its new CFO. David has over 20 years of experience in biopharma and healthcare finance. ATNM shares rose 2% in pre-market trading.

Original reporting
rttnews.com
Published Oct 15, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Actinium Pharmaceuticals Names Matt David CFO — source image
Source · rttnews.com
Decision brief

The 30-second read

$ATNMBullishLow
01

Why it matters

The CFO appointment could improve financial oversight and support upcoming capital raises.

02

Market read

Executive change with a modest pre‑market price reaction; relevant for short‑term traders monitoring biotech leadership moves.

03

What to watch

Matt David's background in investment banking could signal upcoming financing activities not yet disclosed.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Actinium Pharmaceuticals is a clinical‑stage biotech developing targeted radiotherapies for cancer.

Company-level read

Ticker impact

$ATNMBullishMedium confidence
Context

Actinium announced Matt David as CFO; shares rose ~2% pre‑market.

Expected impact

likely modest upside as investors price in fresh leadership

Evidence & confidence

Executive hires are typically neutral to mildly positive; the 2% pre‑market gain suggests market optimism.

Market effects

Sector

May signal continued focus on radiotherapy development within biotech sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche oncology investors.

Counterpoint

What could challenge this read

CFO changes can be routine; the 2% move may be short‑lived if no substantive strategic shift follows.

Key entities

  • Executive
    Matt David

    New Chief Financial Officer with 20+ years in biopharma finance.

  • Company
    Actinium Pharmaceuticals, Inc.

    Developer of targeted radiotherapy products.

Read at source← All news

Related articles

OCT 15
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals (ATNM) announced early Phase 1 trial results for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), to be presented at EANM 2026. The study assesses safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, aiming to inform therapeutic dosing with Actinium-225-labeled ATNM-400.

prnewswire.com2 min
OCT 15
$ATNMMedAI 8/10

Some prostate cancers progress after targeted therapy. Actinium is testing radiation aimed at a different target.

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

stocktitan.net2 min
AUG 14
$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

prnewswire.com4 min
MAY 29
$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

prnewswire.com3 min
MAY 29
$ATNMMedAI 9/10

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

prnewswire.com4 min
OCT 15
$NFLXMed

Bela Bajaria Is Out at Netflix, Peter Rice Is In

Netflix announced Bela Bajaria is stepping down as Chief Content Officer, replaced by Peter Rice. Ted Sarandos praised her decade of service. This follows Netflix's recent layoffs of 1,000 employees. Bajaria led content expansion, including unscripted programming and live events.

vulture.com2 min